NKIND
Live / Applied — Fourth extension granted (statement of use) (as of 03 Feb 2026)
What this means for you
Not registered yet, but its 02 Feb 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97777750
- Mark type
- Stylized text
- Filed
- 02 Feb 2023
- Published for opposition
- 12 Dec 2023
- Attorney of record
- Alicia M. Passerin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases for scientific, clinical, medicinal, and therapeutic purposes; pharmaceutical preparations and substances for the prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; biological preparations for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases and infectious diseases in the fields of immunotherapy, and immuno-oncology; anti-infectives for medical use for the treatment and prevention of immunologic dysfunction, autoimmune diseases, and infectious diseases
- Class 042 — Scientific and technological services: Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases
- Class 044 — Medical, beauty and agricultural services: Medical services; medical information; providing a website featuring medical information in the fields of immunotherapy; providing a website featuring medical information in the fields of oncology, cancer, immune-oncology, autoimmune diseases, and infectious diseases; providing medical information relating to pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases
Owner
- ImmunityBio, Inc., San Diego, CA, US
- ImmunityBio, Inc., San Diego, CA, US
Prosecution history
- 04 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Feb 2026 — SOU EXTENSION 4 GRANTED
- 03 Feb 2026 — SOU EXTENSION 4 FILED
- 03 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 25 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jul 2025 — SOU EXTENSION 3 GRANTED
- 24 Jul 2025 — SOU EXTENSION 3 FILED
- 24 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Jan 2025 — SOU EXTENSION 2 GRANTED
- 16 Jan 2025 — SOU EXTENSION 2 FILED
- 16 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Jun 2024 — SOU EXTENSION 1 GRANTED
- 19 Jun 2024 — SOU EXTENSION 1 FILED